Radius Health (RDUS) Trading Down 7.6%

Radius Health (NASDAQ:RDUS) was down 7.6% during mid-day trading on Monday . The stock traded as low as $28.69 and last traded at $29.01. Approximately 1,005,811 shares changed hands during mid-day trading, an increase of 24% from the average daily volume of 814,154 shares. The stock had previously closed at $31.39.

Several equities research analysts recently issued reports on RDUS shares. Cantor Fitzgerald set a $58.00 price objective on shares of Radius Health and gave the company a “buy” rating in a research note on Thursday, March 22nd. Citigroup reaffirmed a “hold” rating and issued a $43.00 price objective on shares of Radius Health in a research note on Monday, January 22nd. ValuEngine raised shares of Radius Health from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Leerink Swann started coverage on shares of Radius Health in a research note on Thursday, March 29th. They issued an “outperform” rating and a $53.00 price objective for the company. Finally, Morgan Stanley lifted their price objective on shares of Radius Health from $57.00 to $61.00 and gave the company an “overweight” rating in a research note on Friday, March 2nd. Three research analysts have rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $50.89.

The firm has a market capitalization of $1.43 billion, a P/E ratio of -5.00 and a beta of 1.27. The company has a current ratio of 6.55, a quick ratio of 6.41 and a debt-to-equity ratio of 0.87.

Radius Health (NASDAQ:RDUS) last announced its earnings results on Thursday, May 10th. The biopharmaceutical company reported ($1.37) EPS for the quarter, topping the consensus estimate of ($1.46) by $0.09. The firm had revenue of $14.50 million for the quarter, compared to the consensus estimate of $13.80 million. Radius Health had a negative net margin of 706.11% and a negative return on equity of 108.95%. During the same quarter last year, the firm posted ($1.32) EPS. equities analysts expect that Radius Health will post -5.24 earnings per share for the current year.

In other news, major shareholder Growth N. V. Biotech bought 80,000 shares of the company’s stock in a transaction that occurred on Friday, March 2nd. The shares were purchased at an average price of $32.52 per share, for a total transaction of $2,601,600.00. Following the acquisition, the insider now directly owns 5,853,799 shares of the company’s stock, valued at approximately $190,365,543.48. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Growth N. V. Biotech bought 40,000 shares of the company’s stock in a transaction that occurred on Thursday, April 19th. The stock was purchased at an average price of $33.80 per share, for a total transaction of $1,352,000.00. Following the acquisition, the insider now directly owns 6,050,913 shares in the company, valued at $204,520,859.40. The disclosure for this purchase can be found here. Insiders purchased a total of 170,000 shares of company stock worth $5,782,600 in the last quarter. Insiders own 3.42% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Schwab Charles Investment Management Inc. raised its holdings in Radius Health by 0.9% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 182,575 shares of the biopharmaceutical company’s stock worth $5,801,000 after acquiring an additional 1,674 shares during the period. California Public Employees Retirement System increased its holdings in shares of Radius Health by 2.3% during the 4th quarter. California Public Employees Retirement System now owns 74,400 shares of the biopharmaceutical company’s stock worth $2,364,000 after purchasing an additional 1,700 shares during the period. Jane Street Group LLC increased its holdings in shares of Radius Health by 24.7% during the 4th quarter. Jane Street Group LLC now owns 10,043 shares of the biopharmaceutical company’s stock worth $319,000 after purchasing an additional 1,988 shares during the period. Swiss National Bank increased its holdings in shares of Radius Health by 5.6% during the 1st quarter. Swiss National Bank now owns 57,000 shares of the biopharmaceutical company’s stock worth $2,049,000 after purchasing an additional 3,000 shares during the period. Finally, Raymond James & Associates increased its holdings in shares of Radius Health by 44.5% during the 4th quarter. Raymond James & Associates now owns 15,224 shares of the biopharmaceutical company’s stock worth $484,000 after purchasing an additional 4,692 shares during the period.

Radius Health Company Profile

Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide that is in Phase III clinical trial to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator that is in Phase I clinical trial to treat breast cancer.

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply